The number of more complex biopharmaceuticals in development continues to increase. These include molecules like virus-like particle vaccines, proteins that require cleavage, or other additional post-translational modifications not typically performed by CHO cells, and more recently, numerous different multi-specific antibody platforms. Each of these classes of molecules requires multiple proteins to be expressed at differing ratios to get the correct biopharmaceutical produced at maximum titer and quality..
In this webinar Catalent experts outline cell line development, upstream process development and process scale-up for Catalent’s SMARTag® technology antibody programs in which the antibody requires additional conversion by a site-specific enzyme for correct functionality.
Click here to view webinar.